Vascepa, approved in the U.S. to reduce triglycerides and cardiovascular events, helped Amarin generate $285.3M in net product revenue in 2023, a ~22% YoY decline from a year ago. More on Amarin ...

Amarin has a 52 week low of $0.43 and a 52 week high of $1.11. The company has a market cap of $217.66 million, a PE ratio of -5.89 and a beta of 1.82. Amarin Corporation plc, a pharmaceutical ...

Shares of Amarin stock opened at $0.58 on Tuesday. The company’s 50-day moving average price is $0.54 and its two-hundred day moving average price is $0.56. Amarin has a 52 week low of $0.43 and ...

Effective 1 April 2025, Austrian Reimbursement Marks 10th National Reimbursement for VAZKEPA® in Europe, Supporting Amarin’s Continued Growth and Development Across the Continent -- DUBLIN ...